Enzymotec (NASDAQ:ENZY) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Several other analysts have also recently weighed in on the company. Wells Fargo & Co lifted their price target on Enzymotec from $9.50 to $12.00 and gave the stock a “market perform” rating in a report on Monday, October 30th. Zacks Investment Research raised Enzymotec from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 17th. Finally, Jefferies Group reissued a “hold” rating and set a $11.50 price target on shares of Enzymotec in a report on Thursday, October 19th. One analyst has rated the stock with a sell rating and four have given a hold rating to the stock. Enzymotec presently has a consensus rating of “Hold” and an average target price of $11.75.

Enzymotec (NASDAQ ENZY) remained flat at $$11.85 during trading hours on Friday. The company had a trading volume of 54,689 shares, compared to its average volume of 101,553. The firm has a market capitalization of $277.62, a price-to-earnings ratio of -43.89, a PEG ratio of 3.19 and a beta of 1.22. Enzymotec has a 1 year low of $6.30 and a 1 year high of $12.35.

A number of large investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC acquired a new stake in Enzymotec during the 2nd quarter worth approximately $2,350,000. State Street Corp lifted its holdings in Enzymotec by 1.8% during the 2nd quarter. State Street Corp now owns 20,952 shares of the biotechnology company’s stock worth $169,000 after purchasing an additional 380 shares during the last quarter. Osborn Williams & Donohoe LLC acquired a new stake in Enzymotec during the 3rd quarter worth approximately $137,000. Finally, JPMorgan Chase & Co. bought a new position in Enzymotec during the 3rd quarter worth $107,000. 15.73% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “BidaskClub Downgrades Enzymotec (ENZY) to Sell” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/01/06/bidaskclub-downgrades-enzymotec-enzy-to-sell.html.

Enzymotec Company Profile

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

Receive News & Ratings for Enzymotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec and related companies with MarketBeat.com's FREE daily email newsletter.